Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
|Videos|August 25, 2015
Dr. Steinberg Discusses the Challenges in Treating Bladder Cancer
Author(s)Gary D. Steinberg, MD
Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of surgery, director, urologic oncology, University of Chicago Medicine, discusses the challenges in treating bladder cancer.
Advertisement
Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of surgery, director, urologic oncology, University of Chicago Medicine, discusses the challenges in treating bladder cancer.
It is a disease of aging, so many patients who have had bladder cancer are older, with multiple additional medical problems, says Steinberg.
Advertisement
Related to this article
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Perioperative enfortumab vedotin plus pembrolizumab had a cost-effectiveness ratio of $72,460 per QALY vs radical cystectomy alone in a 10-year Medicare model.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5